The Command trial enrolled six patients and will test the safety and efficacy of the Synchron Switch motor neuroprosthesis in patients with severe paralysis, according to a Sept. 5 Synchron news release.
For the patients who cannot use their hands, the study will assess how brain-computer interface technology will allow them to complete tasks such as emailing, online shopping and telehealth services with their thoughts.
The research is being conducted under an investigational device exemption awarded to the company by the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
